A better way to study Parkinson’s disease in the lab could lead to … – EurekAlert

image:

Lalitha Madhavan, MD, PhD, and her research team used induced pluripotent stem cell technology to reprogram adult skin cells into brain cells to study Parkinsons disease.

Credit: University of Arizona Health Sciences

A recent study published in Progress in Neurobiology and led by researchers at the University of Arizona College of Medicine Tucson has developed an improved method to study Parkinsons disease in the lab. Along the way, researchers also uncovered clues that may help scientists figure out how to detect Parkinsons earlier and point the way toward better treatments.

Around a million Americans are living with Parkinsons disease, a neurological disorder that causes difficulty in movement, balance and cognition. Symptoms worsen until tasks like walking, talking and swallowing present enormous challenges. While there is no cure, there are treatments that control symptoms but their effectiveness wanes over time and they are associated with unwanted side effects.

Its a slow-developing disorder. We only diagnose the disease at a late stage, when 60-70% of dopamine neurons are dysfunctional or have died off, said Lalitha Madhavan, MD, PhD, associate professor of neurology at the College of Medicine Tucson, part of UArizona Health Sciences. We have treatments, but at that point youre trying to throw a small glass of water on a raging fire. Being able to diagnose the condition at the earliest stages would be a big step.

Madhavans team used cells from Parkinsons patients to create a human-derived laboratory model to study the disease. Using induced pluripotent stem cell technology a powerful technique that transforms adult cells into embryo-like cells that can then mature into any cell type the lab reprogrammed adult skin cells called fibroblasts into brain cells.

Using the reprogrammed neurons, Madhavan Lab researchers discovered several changes in the cells from Parkinsons subjects that differentiated them from cells of healthy individuals. Madhavan hopes this finding can form the basis for better cell-culture systems for studying Parkinsons disease in the lab, potentially leading to improved diagnostics and treatments.

The experiments also showed that skin cells may act as a window into the brain. Skin cells dont cause neurological symptoms, but some of the same changes that damage brain cells might also affect skin cells, producing similar molecular signatures.

We wanted to make neurons from skin biopsies using this fantastic technology; however, we noted along the way that the fibroblasts themselves seemed to have signatures that differentiated individuals with Parkinsons. We started to dig deeper into that, Madhavan said. Its exciting that weve shown that connection, and that it tells us skin cells could perhaps be used to diagnose the disease early.

The team hopes that, in the future, doctors will be able to catch Parkinsons disease earlier by examining skin cells for signs that the disease is brewing.

This could be a system in which we could very carefully diagnose people at early stages, Madhavan said, adding that her team received a patent on a method for examining skin cells for molecular signs that correlate to Parkinsons disease.

They are now investigating how skin cells change over time to learn more about how the disease progresses and how to identify it early. Tech Launch Arizona, the University of Arizonas technology commercialization office, is helping protect the innovation and developing strategies to take it from the laboratory to the marketplace where it can impact the lives patients and their doctors.

Madhavan says that if we could catch Parkinsons disease earlier, doctors could prescribe currently available treatments that can slow disease progression. Simultaneously, scientists could work to develop next-generation Parkinsons drugs that target the disease in its early stages.

Because a patients skin cells are easy to access especially compared to brain cells Madhavan also hopes the system could be used for a precision-medicine approach, matching patients with optimized treatments based on a skin biopsy and lab test showing which drug might work best based on their unique genetic profile.

Weve been putting Parkinsons into one big bucket when actually different people express it differently, she said. This system would allow us to carefully classify Parkinsons and assess treatments more effectively based on such a classification.

The lead authors on the study were Mandi Corenblum, MS, senior research specialist, and Aiden McRobbie-Johnson, physiological sciences graduate student. Co-authors include Kelsey Bernard and Timothy Maley, graduate students in neuroscience and physiological sciences; Emma Carruth, undergraduate student in physiology; Moulun Luo, PhD, associate research professor of medicine; Lawrence Mandarino, PhD, professor of medicine; Maria Sans-Fuentes, PhD, BIO5 Institute statistician; Dean Billheimer, PhD, professor in the UArizona Mel and Enid Zuckerman College of Public Health and director of statistical consulting at the BIO5 Institute; and Erika Eggers, PhD, professor of physiology and member of the BIO5 Institute.

The study was supported mainly by a Michael J Fox Foundation grant (MJFF 18366) and in part by grants from the National Eye Institute, a division of the National Institutes of Health, under award nos. R01EY026027 and NSF1552184.

Progress in Neurobiology

Randomized controlled/clinical trial

Cells

Parallel neurodegenerative phenotypes in sporadic Parkinsons disease fibroblasts and midbrain dopamine neurons

22-Oct-2023

Declaration of Competing Interest None.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

More:
A better way to study Parkinson's disease in the lab could lead to ... - EurekAlert

Lab-grown ‘small blood vessels’ point to potential treatment for major … – EurekAlert

image:

Disease mural cells stained for calponin (mural cells marker, green), collagen IV (magenta) and DAPI (nuclei, blue)

Credit: Alessandra Granata/University of Cambridge

Cambridge scientists have grown small blood vessel-like models in the lab and used them to show how damage to the scaffolding that supports these vessels can cause them to leak, leading to conditions such as vascular dementia and stroke.

The study, published today in Stem Cell Reports, also identifies a drug target to plug these leaks and prevent so-called small vessel disease in the brain.

Cerebral small vessel disease (SVD) is a leading cause of age-related cognitive decline and contributes to almost half (45%) of dementia cases worldwide. It is also responsible for one in five (20%) ischemic strokes, the most common type of stroke, where a blood clot prevents the flow of blood and oxygen to the brain.

The majority of cases of SVD are associated with conditions such as hypertension and type 2 diabetes, and tend to affect people in their middle age. However, there are some rare, inherited forms of the disease that can strike people at a younger age, often in their mid-thirties. Both the inherited and spontaneous forms of the disease share similar characteristics.

Scientists at the Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, used cells taken from skin biopsies of patients with one of these rare forms of SVD, which is caused by a mutation in a gene called COL4.

By reprogramming the skin cells, they were able to create induced pluripotent stem cells cells that have the capacity to develop into almost any type of cell within the body. The team then used these stem cells to generate cells of the brain blood vessels and create a model of the disease that mimics the defects seen in patients brain vessels.

Dr Alessandra Granata from the Department of Clinical Neurosciences at Cambridge, who led the study, said: Despite the number of people affected worldwide by small vessel disease, we have little in the way of treatments because we dont fully understand what damages the blood vessels and causes the disease. Most of what we know about the underlying causes tends to come from animal studies, but they are limited in what they can tell us.

Thats why we turned to stem cells to generate cells of the brain blood vessels and create a disease model in a dish that mimics what we see in patients.

Our blood vessels are built around a type of scaffolding known as an extracellular matrix, a net-like structure that lines and supports the small blood vessels in the brain. The COL4 gene is important for the health of this matrix.

In their disease model, the team found that the extracellular matrix is disrupted, particularly at its so-called tight junctions, which zip cells together. This leads to the small blood vessels becoming leaky a key characteristic seen in SVD, where blood leaks out of the vessels and into the brain.

The researchers identified a class of molecules called metalloproteinases (MMPs) that play a key role in this damage. Ordinarily, MMPs are important for maintaining the extracellular matrix, but if too many of them are produced, they can damage the structure similar to how in The Sorcerers Apprentice, a single broom can help mop the floor, but too many wreak havoc.

When the team treated the blood vessels with drugs that inhibit MMPs an antibiotic and anti-cancer drug they found that these reversed the damage and stopped the leakage.

Dr Granata added: These particular drugs come with potentially significant side effects so wouldnt in themselves be viable to treat small vessel disease. But they show that in theory, targeting MMPs could stop the disease. Our model could be scaled up relatively easily to test the viability of future potential drugs.

The study was funded by the Stroke Association, British Heart Foundation and Alzheimers Society, with support from the NIHR Cambridge Biomedical Research Centre and the European Unions Horizon 2020 Programme.

Reference Al-Thani, M, Goodwin-Trotman, M. A novel human 1 iPSC model of COL4A1/A2 small vessel disease unveils a key pathogenic role of matrix metalloproteinases. Stem Cell Reports; 16 Nov 2023; DOI: https://doi.org/10.1016/j.stemcr.2023.10.014

Stem Cell Reports

Experimental study

Cells

A novel human 1 iPSC model of COL4A1/A2 small vessel disease unveils a key pathogenic role of matrix metalloproteinases

16-Nov-2023

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See the original post:
Lab-grown 'small blood vessels' point to potential treatment for major ... - EurekAlert

Vitamin B12 is a limiting factor for induced cellular plasticity and … – Nature.com

Animal procedures

Animal experimentation at the IRB Barcelona was performed according to protocols approved by the Science Park of Barcelona (PCB) Ethics Committee for Research and Animal Welfare. Mice were housed in a specific pathogen-free facility on a 12-hour lightdark cycle at an ambient temperature of 2024C and humidity of 3070%. Adult mice were fed ad libitum with SAFE R40 pellet diet (https://safe-lab.com/safe_en/) containing 0.02mg per kg body weight vitamin B12. In general, mice of 816 weeks of age of both sexes were treated with 1mg ml1 doxycycline hyclate BioChemica (PanReac, A2951) in the drinking water (supplemented with 7.5% sucrose) for 7d. Antibiotic treatment was conducted using a broad-spectrum cocktail (1mg l1 each of ampicillin (BioChemica, A0839), neomycin sulfate and metronidazole (Sigma, M1547); 0.5mg l1 vancomycin (Cayman Chemical, CAY-15327) all dissolved in water supplemented with 7.5% sucrose) for 3 weeks before doxycycline initiation and was maintained during doxycycline treatment. Vitamin B12 (Sigma, V2876) supplementation was provided at 1.25mg l1 and folate supplementation was provided as folic acid (Sigma, F7876) at 40mg l1 in the drinking water, both for 7d concomitant with doxycycline treatment. For the B12 bolus experiment, mice were administered 5g vitamin B12 (Sigma, V2876) dissolved in water by oral gavage on day 6 after the start of doxycycline treatment, and blood samples were taken by submandibular collection just before and 24h after the bolus. OSKM transgenic mice are the i4F-B strain (derived on a C57/BL6J background and bred in house) described in ref. 3 and are available upon request. WT mice were i4F-B WT littermate controls where specified, or WT C57/BL6J (Charles River France).

Mice were treated with 2.5% (wt/vol) DSS, colitis grade (36,00050,000; MP Biomedicals, MFCD00081551) in drinking water for 5 consecutive days. On day 5, the DSS was removed and drinking water was supplemented with doxycycline hyclate BioChemica (1mg ml1; PanReac, A2951; with 7.5% sucrose) for 48h, after which regular water was returned. Mice in the B12 experimental group also received supplementation of vitamin B12 (1.25mg l1; Sigma, V2876) from the point of DSS removal (that is, day 5) until experimental endpoint. The MAT2Ai group received FIDAS-5 (MedChemExpres, HY-136144) and were dosed with 20mg per kg body weight per day dissolved in PEG400 by oral gavage as previously described79.

On day 9 (relative to the start of DSS administration), food was withdrawn from mice for 4h, after which mice were gavaged with FITCdextran (MW 4,000; Sigma-Aldrich, FD4) at a dose of 44mg per 100g of body weight dissolved in PBS. Food restriction was maintained for 3 additional hours, at which point blood was sampled by submandibular vein bleeding. Whole blood was diluted at a ratio of 1:4 in PBS, and 100l of blood/PBS mixture from each mouse was loaded into a 96-well plate. Fluorescence intensity was measured on a BioTek Synergy H1 Microplate Reader (excitation 490nm; emission 520nm).

Fresh stool samples were collected directly from mice and snap frozen. gDNA was isolated using a QIAamp DNA Stool Mini Kit (QIAGEN, 51504) according to the manufacturers protocols.

Libraries were prepared using the NEBNext Ultra DNA Library Prep Kit for Illumina (E7370L) according to the manufacturers protocol. Briefly, 50ng of DNA was fragmented to approximately 400bp and subjected to end repair plus A-tailing, ligation of NEB adaptor and Uracil excision by USER enzyme. Then, adaptor-ligated DNA was amplified for eight cycles by PCR using indexed primers. All purification steps were performed using AMPure XP Beads (A63881). Final libraries were analysed using an Agilent DNA 1000 chip to estimate the quantity and check size distribution, and were then quantified by qPCR using the KAPA Library Quantification Kit (KK4835, KapaBiosystems) before amplification with Illuminas cBot. Libraries were sequenced (2125bp) on Illuminas HiSeq 2500.

Reads were aligned to the mm10 genome using STAR 2.7.0a with default parameters80. DNA contaminated reads were filtered out from the analysis. The first and final ten bases of the non-contaminated reads were trimmed using DADA2 1.10.1 (ref. 81). Taxonomic assignments were carried out through Kaiju 1.7.0 (ref. 82) using the microbial subset of the NCBI BLAST non-redundant protein database (nr). Resulting sequencing counts were aggregated at genus level. Reads that could not be assigned to any specific genus were classified to the nearest known taxonomic rank (marked by the term _un). The gut microbial compositional plot displays the relative abundances (percentage) at genus level. Only the 17 most abundant taxa are shown, while the rest were moved to the others category. For all genera, the treatment effect (finish versus start) was compared between OSKM and control (WT) mice. This was accounted in a model with an interaction term (drug:treatment) using DESeq2 with default options83. The paired nature of the experimental design was taken into account in the model as an adjusting factor.

Decontamination from host and trimming was done following the same routines as for the taxonomic analysis. Cleaned sequences for all samples were assembled into contigs using megahit 1.2.4 (ref. 84), and prodigal 2.6.3 (ref. 85) was then used to predict the open reading frames inside the obtained contigs. Protein mapping and KEGG and COG annotations were obtained using the EggNOG mapper 2.0.0 (ref. 86). The abundance of the annotated genes was finally measured by counting aligned reads to them via Bowtie2, version 2.2.2, under default parameters87. Resulting counts data were aggregated at protein level. The treatment effect (finish versus start) was compared between OSKM and control (WT) mice. This was accounted in a model with an interaction term (drug:treatment) using DESeq2 with default options83. The paired nature of the experimental design was considered in the model as an adjusting factor. The top 500 protein hits from the fitted model (nondirectional set) as well as the top 200 positive hits and the top 200 negative hits (directional sets), in all cases ordered by statistical significance, were used to explore enrichment of functional annotations. In this regard, GO terms for bacteria and archaea were considered using the AmiGO 2 GO annotations database88, removing from the analysis gene sets with few genes (less than 8) and too many genes (more than 499). Statistically enriched GO terms were identified using the standard hypergeometric test. Significance was defined by the adjusted P value using the Benjamini and Hochberg multiple-testing correction. To take into consideration the compositional nature of the data, all DESeq2-based results were complemented with graphical representations of abundance log-ratio (between finish and start matched samples) rankings. This provides a scale invariant way (with regard to the total microbial load) to present the data89.

Blood was collected via submandibular vein bleed (D0, D2, D4) or intracardiac puncture following deep carbon dioxide anaesthetisation (D7) at approximately 12:0014:00h (46h into the light cycle) of each day. Whole blood was spun down for 10min at 3,381g at 4C and supernatant (serum) was separated and stored at 80C.

Acetonitrile (Sigma-Aldrich), isopropanol (Sigma-Aldrich), methanol (Sigma-Aldrich), chloroform (Sigma-Aldrich), acetic acid (Sigma-Aldrich), formic acid (Sigma-Aldrich), methoxyamine hydrochloride (Sigma-Aldrich), MSTFA (N-methyl-N-(trimethylsilyl) trifluoroacetamide; Sigma-Aldrich), pyridine (Sigma-Aldrich), 3-nitrophenylhydrazine (Sigma-Aldrich), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC; Sigma-Aldrich) and sulfosalicylic acid (Sigma-Aldrich) as previously described90.

A volume of 25l of serum were mixed with 250l a cold solvent mixture with ISTD (methanol/water/chloroform, 9:1:1, 20C), into 1.5ml microtube, vortexed and centrifugated (10min at 15,000g, 4C). The upper phase of supernatant was split into three parts: 50l was used for gas chromatography coupled to mass spectrometry (GCMS) experiments in the injection vial, 30l was used for the short-chain fatty acid ultra-high performance liquid chromatography (UHPLC)MS method, and 50l was used for other UHPLCMS experiments.

The GCMS/MS method was performed on a 7890B gas chromatography system (Agilent Technologies) coupled to a triple-quadrupole 7000C (Agilent Technologies) equipped with a high-sensitivity electronic impact source (EI) operating in positive mode.

Targeted analysis was performed on an RRLC 1260 system (Agilent Technologies) coupled to a triple-quadrupole 6410 (Agilent Technologies) equipped with an electrospray source operating in positive mode. Gas temperature was set to 325C with a gas flow of 12l min1. Capillary voltage was set to 4.5kV.

Targeted analysis was performed on an RRLC 1260 system (Agilent Technologies) coupled to a triple-quadrupole 6410 (Agilent Technologies) equipped with an electrospray source operating in positive mode. The gas temperature was set to 350C with a gas flow of 12l min1. The capillary voltage was set to 3.5kV.

Targeted analysis was performed on an RRLC 1260 system (Agilent Technologies) coupled to a 6500+QTRAP (Sciex) equipped with an electrospray ion source.

The profiling experiment was performed with a Dionex Ultimate 3000 UHPLC system (Thermo Scientific) coupled to a Q-Exactive (Thermo Scientific) equipped with an electrospray source operating in both positive and negative mode and full scan mode from 100 to 1,200m/z. The Q-Exactive parameters were: sheath gas flow rate, 55 arbitrary units (a.u.); auxiliary gas flow rate, 15 a.u.; spray voltage, 3.3kV; capillary temperature, 300C; S-Lens RF level, 55V. The mass spectrometer was calibrated with sodium acetate solution dedicated to low mass calibration.

The peak areas (corrected to quality control) corresponding to each annotated metabolite identified in the serum of reprogrammable mice (n=6 per group) at day 5 and day 7 after doxycycline treatment were converted to log2 values. Data were represented as log2 fold change (log2 FC) values to each mouse at day 0 (before doxycycline administration). Metabolic pathway impact was calculated by Global ANOVA pathway enrichment and Out-degree Centrality Topology analysis through the MetaboAnalyst 4.0 software91, using KEGG library (2019) as a reference. The colour gradient from white to red indicates the P value, where red is most significant. Bubble size indicates the relative contribution of the detected metabolites in their respective KEGG pathway. Pathway impact scores the centrality of the detected metabolites in the pathway.

A total of 30l of mouse plasma was acidified with 3l solution of 15% phosphoric acid (vol/vol). Afterwards, 42l of methyl tert-butyl ether was added and vigorously mixed using a vortex. After 20min of reequilibration, samples were centrifuged for 10min at 21,130g at 4C. Next, 90l of acetonitrile were added to 10l of the aqueous phase to facilitate protein precipitation. After another cycle of centrifugation, the supernatant was transferred into a vial before LCMS analysis.

The extracts were analysed by a UHPLC system coupled to a 6490 triple-quadrupole mass spectrometer (QqQ, Agilent Technologies) with electrospray ion source (LCESIQqQ) working in positive mode. The injection volume was 3l. An ACQUITY UPLC BEH HILIC column (1.7m, 2.1150mm, Waters) and a gradient mobile phase consisting of water with 50mM ammonium acetate (phase A) and acetonitrile (phase B) were used for chromatographic separation. The gradient was as follows: isocratic for 2min at 98% B, from 2 to 9min decreased to 50% B, for 30s raised to 98%, and finally column equilibrated at 98% B until 13min. The flow rate was 0.4ml min1. The mass spectrometer parameters were as follows: drying and sheath gas temperatures, 270C and 400C, respectively; source and sheath gas flow rates, 15 and 11l min1, respectively; nebulizer flow, 35psi; capillary voltage, 3,000V; nozzle voltage, 1,000V; and iFunnel HRF and LRF, 130 and 100V, respectively. The QqQ worked in MRM mode using defined transitions. The transitions for doxycycline and the collision energy (CE(V)) were 445428(17), 44598(60).

In total, 25l of serum was mixed with 25l of TCEP and 70l of 1% formic acid in methanol. Samples were vortexed and left at 20C for 1h, centrifuged for 10min at 21,130g and 4C and transferred to glass vials for their analysis by LCMS.

LCMS was performed with a Thermo Scientific Vanquish Horizon UHPLC system interfaced with a Thermo Scientific Orbitrap ID-X Tribrid Mass Spectrometer.

Metabolites were separated by HILIC chromatography with an InfinityLab Poroshell 120 HILIC-Z 2.7m, 2.1mm100mm column (Agilent Technologies). The mobile phase A was 50mM ammonium acetate in water, and mobile phase B was acetonitrile. Separation was conducted under the following gradient: 02min, isocratic 90% B; 26min raised to 50% B; 67min, isocratic 50% B; 77.2min, increased to 90% B; 7.210.5min, reequilibration column 90% B. The flow rate was 0.4ml min1. The injection volume was 5l.

Samples were analysed in positive mode in targeted SIM mode and the following setting: isolation window (m/z), 4; spray voltage, 3,500V; sheath gas, 50 a.u.; auxiliary gas, 10 a.u.; ion transfer tube temperature, 300C; vaporizer temperature, 300C; Orbitrap resolution, 120,000; RF lens, 60%; AGC target, 2e5; maximum injection time, 200ms.

SAM (m/z 399.145) was monitored from 57min; Met (m/z 150.0583) from 3.25.2min; SAH (m/z 385.1289) from 46min; Hcy (m/z 136.0428) from 3.45.5min, as previously optimized using pure standards.

Approximately, 20mg of dry and pulverized stool samples were mixed with with 75l of TCEP and 210l of 1% formic acid in methanol. Samples were vortexed and subjected to three freezethaw cycles using liquid nitrogen. Subsequently, samples were left in ice for 1h, centrifuged for 10min at 21,130g and 4C and transferred to glass vials for their analysis by LCMS.

LCMS was performed with a Thermo Scientific Vanquish Horizon UHPLC system interfaced with a Thermo Scientific Orbitrap ID-X Tribrid Mass Spectrometer.

Metabolites were separated by HILIC chromatography with an InfinityLab Poroshell 120 HILIC-Z 2.7m, 2.1mm100mm column (Agilent Technologies). The mobile phase A was 50mM ammonium acetate in water, and mobile phase B was acetonitrile. Separation was conducted under the following gradient: 02min, isocratic 90% B; 26min raised to 50% B; 67min, isocratic 50% B; 77.2min, increased to 90% B; 7.210.5min, reequilibration column 90% B. The flow was 0.4ml min1. The injection volume was 5l.

Samples were analysed in positive mode in targeted SIM mode and the following setting: isolation window (m/z), 4; spray voltage, 3,500V; sheath gas, 50 a.u.; auxiliary gas, 10 a.u.; ion transfer tube temperature, 300C; vaporizer temperature, 300C; Orbitrap resolution, 120,000; RF lens, 60%; AGC target, 2e5; maximum injection time, 200ms. Cyanocobalamin was monitored from (m/z 1355.5747 and m/z 678.291) from 55.5min, as previously optimized using a pure standard.

Mouse serum was diluted at a 1:20 ratio in PBS and holotranscobalamin (holoTC) was measured using an ADVIA Centuar Immunoassay System (SIEMENS) with ADVIA Centuar Vitamin B12 Test Packs (07847260) according to the manufacturers instructions.

Cell pellets were mixed with 50l of TCEP and 140l of 1% formic acid in methanol (containing 150g l1 of Tryptophan-d5 as internal standard). Samples were vortexed and subjected to three freezethaw cycles using liquid nitrogen. Subsequently, samples were left at 20C for 1h, centrifuged for 10min at 21,130g and 4C and transferred to glass vials for their analysis by LCMS/MS.

Samples were analysed with an UHPLC 1290 Infinity II Series coupled to a QqQ/MS 6490 Series from Agilent Technologies (Agilent Technologies). The source parameters applied operating in positive electrospray ionization (ESI) were gas temperature: 270C; gas flow: 15l min1; nebulizer: 35psi; sheath gas heater, 400 a.u.; sheath gas flow, 11 a.u.; capillary, 3,000V; nozzle voltage: 1,000V.

The chromatographic separation was performed with an InfinityLab Poroshell 120 HILIC-Z 2.7m, 2.1mm100mm column (Agilent Technologies), starting with 90% B for 2min, 50% B from minute 2 to 6, and 90% B from minute 7 to 7.2. Mobile phase A was 50mM ammonium acetate in water, and mobile phase B was acetonitrile. The column temperature was set at 25C and the injection volume was 2l.

MRM transitions for SAM (RT: 6.1min) were 399298 (4V), 399250 (12V), 39997 (32V) and 399136 (24V) for M+0, and 400299 (4V), 400251 (12V), 40097 (32V), 400137 (24V), 400250 (12V) and 400136 (24V) for M+1.

Samples were fixed overnight at 4C with neutral buffered formalin (HT501128-4L, Sigma-Aldrich). Paraffin-embedded tissue sections (23m in thickness) were air-dried and further dried at 60C overnight for immunohistochemical staining.

Sections were stained with haematoxylin and eosin (H&E) for histological evaluation by a board-certified pathologist who was blinded to the experimental groups. Additionally, periodic acidSchiff staining (AR16592-2, Artisan, Dako, Agilent) was used to visualize mucus-producing cells on 34-m sections of colon that were counterstained with haematoxylin.

In the reprogramming model, the findings were evaluated by focusing mainly on the appearance of hyperplastic and dysplastic changes of the epithelial cells of the digestive mucosa and pancreatic acini. Inflammation and loss of the intestinal goblet cells were also reported. To document the severity and extension, a semi-quantitative grading system was used based on previously used histological criteria:

Gastric and colon mucosa inflammatory cell infiltrate and multifocal areas of crypt (large intestine) or glandular (stomach) epithelial cell dysplasia were scored from 0 to 5, where 0 indicates absence of lesion and 5 indicates very intense lesions.

Intestinal crypt hyperplasia: 1, slight; 2, twofold to threefold increase of the crypt length; 3, >threefold increase of the crypt length.

Goblet cell loss of the mucosa of the large intestine: 1, <10% loss; 2, 1050% loss; 3, >50% loss.

Histological total score was presented as a sum of all parameters scored for a given tissue.

In the colitis model, the following parameters were semi-quantitatively evaluated as previously described92 as follows:

Inflammation of the colon mucosa: 0, none; 1, slight, 2, moderate; 3, severe.

Depth of the injury: 0, none; 1, mucosa; 2, mucosa and submucosa; 3, transmural.

Crypt damage: 0, none; 1, basal and 1/3 damaged; 2, basal and 2/3 damaged; 3, only the surface epithelium intact; 4, entire crypt and epithelium lost.

Tissue involvement: 0, none; 1, 025%; 2, 2650%; 3, 5175%; 4, 76100%.

The score of each parameter was multiplied by the factor of tissue involvement and summed to obtain the total histological score.

Immunohistochemistry was performed using a Ventana discovery XT for NANOG and Sca1/Ly6A/E, the Leica BOND RX Research Advanced Staining System for H3K36me3, keratin 14 and vitamin B12, and manually for Ki67. Antigen retrieval for NANOG was performed with Cell Conditioning 1 buffer (950-124, Roche) and for Sca1/Ly6A/E with Protease 1 (5266688001, Roche) for 8min followed with the OmniMap anti-Rat HRP (760-4457, Roche) or OmniMap anti-Rb HRP (760-4311, Roche). Blocking was done with casein (760-219, Roche). Antigenantibody complexes were revealed with ChromoMap DAB Kit (760-159, Roche). For H3K36me3 and keratin 14, antigen retrieval was performed with BOND Epitope Retrieval 1 (AR9961, Leica) and for vit B12 with BOND Epitope Retrieval Solution 2 (Leica Biosystems, AR9640) for 20min, whereas for Ki67, sections were dewaxed as part of the antigen retrieval process using the low pH EnVision FLEX Target Retrieval Solutions (Dako) for 20min at 97C using a PT Link (Dako-Agilent). Blocking was performed with Peroxidase-Blocking Solution at room temperature (RT; S2023, Dako-Agilent) and 5% goat normal serum (16210064, Life technology) mixed with 2.5% BSA diluted in wash buffer for 10 and 60min at RT. Vitamin B12 also was blocked with Vector M.O.M. Blocking Reagent (MK-2213, Vector) following the manufacturers procedures for 60min. Primary antibodies were incubated for 30, 60 or 120min. The secondary antibody used was the BrightVision poly HRP-Anti-Rabbit IgG, incubated for 45min (DPVR-110HRP, ImmunoLogic) or the polyclonal goat Anti-Mouse at a dilution of 1:100 for 30min (Dako-Agilent, P0447). Antigenantibody complexes were revealed with 3-3-diaminobenzidine (K346811, Agilent or RE7230-CE, Leica). Sections were counterstained with haematoxylin (CS700, Dako-Agilent or RE7107-CE, Leica) and mounted with Mounting Medium, Toluene-Free (CS705, Dako-Agilent) using a Dako CoverStainer. Specificity of staining was confirmed by staining with a rat IgG (6-001-F, R&D Systems, Bio-Techne), a Rabbit IgG (ab27478, Abcam) or a mouse IgG1, kappa (Abcam, ab18443) isotype controls. See Supplementary Table 5 for primary antibody details.

Ready-to-use reagents from RNAscope 2.5 LS Reagent Kit-RED (322150, RNAScope, ACD Bio-Techne) were loaded onto the Leica Biosystems BOND RX Research Advanced Staining System according to the user manual (322100-USM). FFPE tissue sections were baked and deparaffinized on the instrument, followed by epitope retrieval (using Leica Epitope Retrieval Buffer 2 at 95C for 15min) and protease treatment (15min at 40C). Probe hybridization, signal amplification, colorimetric detection and counterstaining were subsequently performed following the manufacturers recommendations.

Hybridization was performed with the RNAscope LS 2.5 Probe - Mm-Lgr5 - Mus musculus leucine rich repeat containing G-protein-coupled receptor 5 (312178, RNAScope, ACD Bio-Techne). Control probe used was the RNAscope 2.5 LS Probe - Mm-UBC - Mus musculus ubiquitin C (Ubc), as a housekeeping gene (310778, RNAScope - ACD Bio-Techne). The bacterial probe RNAscope 2.5 LS Negative Control Probe_dapB was used as a negative control (312038, RNAScope - ACD Bio-Techne).

Brightfield images were acquired with a NanoZoomer-2.0 HT C9600 digital scanner (Hamamatsu) equipped with a 20 objective. All images were visualized with a gamma correction set at 1.8 in the image control panel of the NDP.view 2 U12388-01 software (Hamamatsu, Photonics).

Brightfield images of immunohistochemistry were quantified using QuPath software93 with standard detection methods. Where the percentage of tissue staining is calculated, pixels were classified as positive and negative using the Thresholder function. Where the percentage of cells is quantified, the Positive Cell Detection function was used.

MEFs were cultured in standard DMEM medium with 10% FBS (Gibco, LifeTechnologies, 10270106) with antibiotics (100U ml1 penicillinstreptomycin; Life Technologies, 11528876). Reprogramming of the doxycycline-inducible 4-Factor (i4F) MEFs with inducible expression of the four Yamanaka factors Oct4, Sox2, Klf4 and cMyc (OSKM) was performed as previously described3. Briefly, i4F MEFs were seeded at a density of 3105 cells per well in six-well tissue culture plates coated with gelatin and treated with doxycycline (PanReac, A2951) 1mg ml1 continuously to induce expression of the OSKM transcription factors in the presence of complete KSR media (15% (vol/vol) Knockout Serum Replacement (KSR, Invitrogen, 10828028) in DMEM with GlutaMax (Life Technologies, 31966047) basal media, with 1,000U ml1 LIF (Merck, 31966047), non-essential amino acids (Life Technologies, 11140035) and 100M beta-mercaptoethanol (Life Technologies, 31350010) plus antibiotics (penicillinstreptomycin, Gibco, 11528876)), which was replaced every 4872h. After 10d, iPS cell colonies were scored by alkaline phosphatase staining according to the manufacturers protocol (AP blue membrane substrate detection kit, Sigma, AB0300). Vitamin B12 (Sigma, V2876; 2M final), MAT2Ai PF-9366 (MedChemExpress, HY-107778; 2M final), SAM (S-(5-adenosyl)-l-methionine iodide, Merck, A4377; 100M final) and NSC636819 (Sigma-Aldrich, 5.31996; 10M final) were added continuously to the culture media and replaced every 4872h.

Reprogramming of WT MEFs was performed as previously described94. Briefly, HEK-293T (American Type Culture Collection, ATCC-CRL-3216) cells were cultured in DMEM supplemented with 10% FBS and antibiotics (penicillinstreptomycin, Gibco, 11528876). Around 5106 cells per 100-mm-diameter dish were transfected with the ecotropic packaging plasmid pCL-Eco (4g) together with one of the following retroviral constructs (4g): pMXs-Klf4, pMXs-Sox2, pMXs-Oct4 or pMXs-cMyc (obtained from Addgene) using Fugene-6 transfection reagent (Roche) according to the manufacturers protocol. The following day, media were changed and recipient WT MEFs to be reprogrammed were seeded (1.5105 cells per well of a six-well plate). Retroviral supernatants (10ml per plate/factor) were collected serially during the subsequent 48h, at 12-h intervals, each time adding fresh media to the 293T cells cells (10ml). After each collection, supernatant was filtered through a 0.45-m filter, and each well of MEFs received 0.5ml of each of the corresponding retroviral supernatants (amounting to 2ml total). Vitamin B12 supplementation (Sigma, V2876; 2M final concertation) began on the same day as viral transduction. This procedure was repeated every 12h for 2d (a total of four additions). After infection was completed, media were replaced by complete KSR media (see above). Cell pellets were harvested on day 5 (relative to the first infection) and histone extracts were processed for immunoblot as described below. On day 14 (relative to the first infection), iPS cell colonies were scored by alkaline phosphatase staining according to the manufacturers protocol (AP blue membrane substrate detection kit; Sigma, AB0300).

Doxycycline-inducible i4F MEFs were cultured as described in Cell culture above, with 1mg ml1 doxycycline, with without continuous vitamin B12 supplementation. At 72h after the addition of doxycycline, cells were transferred to complete KSR media containing a final concentration of 0.5mM l-Serine-13C3 (Sigma-Aldrich, 604887). This is the same concentration of unlabelled l-serine normally found in the complete KSR media, and was generated by ordering custom, serine-free DMEM (Life Technologies, ME22803L1) and custom, serine-free non-essential amino acid mixture (Life Technologies, ME22804L1). Six hours after the addition of labelled media, a subset of wells was harvested by scraping in PBS and centrifugation (300g for 5min); supernatant was removed and pellets were snap frozen. At 72h after the addition of the labelled media (that is, 6days into reprogramming), cells still in culture were transferred back to unlabelled complete KSR media, which was changed every 4872h. iPS cell colonies were analysed by alkaline phosphatase staining according to the manufacturers protocol (AP blue membrane substrate detection kit; Sigma, AB0300) on day 10. Doxycycline and vitamin B12 supplementation were continuous throughout the entire reprogramming protocol, and replenished with every media change (that is, every 4872h).

i4F MEFs were cultured in the presence doxycycline 2M of vitamin B12 over 3 or 10days (culture conditions as described above) and histone extracts were prepared using EpiQuik Total Histone Extraction Kit (EpiGentek, OP-0006-100) according to the manufacturers instructions. Around 200ng of total histone extract was used per well in the EpiQuik Histone H3 Modification Multiplex Assay Kit (Colorimetric; EpiGentek, P-3100) according to the manufacturers instructions.

Histone extracts were prepared using an EpiQuik Total Histone Extraction Kit (EpiGentek, OP-0006-100) according to the manufacturers instructions and quantified using DC Protein Assay Kit (Bio-Rad, 5000111). Whole-cell extracts were prepared in RIPA buffer (10mM Tris-HCl, pH 8.0; 1mM EDTA; 0.5mM EGTA; 1% Triton X-100; 0.1% sodium deoxycholate; 0.1% SDS; 140mM NaCl). A total of 10g of lysate was loaded per lane and hybridized using antibodies against H3K36me3, MS, vinculin, total histone H3 and LI-COR fluorescent secondary reagents (IRDye 800 CW anti-mouse, 926-32210; IRDye 680 CW anti-mouse, 926-68070; IRDye 800 CW anti-rabbit, 926-32211; IRDye 680 CW anti-mouse, 926-68071) all at a dilution of 1:10,000 according to manufacturers instructions. Immunoblots were visualized on an Odyssey FC Imaging System (LI-COR Biosciences). See Supplementary Table 5 for primary antibody details.

GSEAPreranked was used to perform a GSEA of annotations from MsigDB M13537, with standard GSEA and leading edge analysis settings. We used the RNA-seq gene list ranked by log2 fold change, selecting gene set as the permutation method with 1,000 permutations for KolmogorovSmirnoff correction for multiple testing95.

Genes belonging to the leading edge of the GSEA using the Met derivation signature (MsigDB, M13537) in the pancreas of reprogramming mice were selected. These genes were then compared to genes belonging to the leading edge of the same gene signature from i4F MEFs treated with doxycycline in vitro for 72h, as compared to OSKM MEFs treated with vitamin B12 (that is, genes in MsigDB M13537 whose upregulation was relieved by B12 supplementation in vitro). We selected 11 of these genes for which we had qPCR primers available.

Total RNA was extracted from MEFs with TRIzol (Invitrogen) according to the manufacturers instructions. Up to 5g of total RNA was reverse transcribed into cDNA using the iScript Advanced cDNA Synthesis Kit (Bio-Rad, 172-5038; pancreas) or iScript cDNA Synthesis Kit (Bio-Rad, 1708890; all other organs) for RTqPCR. Real-time qPCR was performed using GoTaq qPCR Master Mix (Promega, A6002) in a QuantStudio 6 Flex thermocycler (Applied Biosystem) or 7900HT Fast Real-Time PCR System (Thermo Fisher). See Supplementary Table 6 for primer sequences.

i4F MEFs were cultured in the presence or absence of doxycycline 2M of vitamin B12 (Merck, V2876) over 3days in six-well plates (culture conditions as described above). Cells were fixed with 1% (vol/vol) PFA (Fisher Scientific, 50980487) for 2min and then quenched with 750mM Tris (PanReac AppliChem, A2264) for 5min. Cells were washed twice with PBS, scraped, and spun down at 1,200g for 5min. Pellets were lysed with 100l (per well) lysis buffer (50mM HEPES-KOH pH 7.5, 140mM HCl, 1mM EDTA pH 8, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, protease inhibitor cocktail; Sigma, 4693159001) on ice for 10min, then sonicated using a Diagenode BioRuptor Pico (Diagenode, B01060010) for ten cycles (30s on, 30s off) at 4C. Lysates were clarified for 10min at 8,000g, 1% input samples were reserved, and supernatant was used for immunoprecipitation with Diagenode Protein A-coated Magnetic beads ChIPseq grade (Diagenode, C03010020-660) and H3K3me3 monoclonal antibody (Cell Signaling Technologies, 4909) with 0.1% BSA (Sigma, 10735094001). The following day, cells were washed once with each buffer: low salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 150mM NaCl), high salt (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl pH 8.0, 5,000mM NaCl), LiCl (0.25M LiCl, 1% NP-40, 1% sodium deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8.0) and eluted in 1% SDS, 100mM NaHCO3 buffer. Cross-links were reversed with RNase A (Thermo Fisher, EN0531), proteinase K (Merck, 3115879001) and sodium chloride (Sigma, 71376), and chromatin fragments were purified using QIAquick PCR purification kit (Qiagen, 28104).

i4F MEFs were cultured in the presence or absence of doxycycline and the indicated compounds over 3days in six-well plates (culture conditions as described above). After 72h, RNA was extracted using an RNeasy Kit (Qiagen, QIA74106) according to the manufacturers instructions.

The concentration of the DNA samples (inputs and immunoprecipitations) was quantified with a Qubit dsDNA HS kit, and fragment size distribution was assessed with the Bioanalyzer 2100 DNA HS assay (Agilent). Libraries for ChIPseq were prepared at the IRB Barcelona Functional Genomics Core Facility. Briefly, single-indexed DNA libraries were generated from 0.51.5ng of DNA samples using the NEBNext Ultra II DNA Library Prep kit for Illumina (New England Biolabs). Eleven cycles of PCR amplification were applied to all libraries.

The final libraries were quantified using the Qubit dsDNA HS assay (Invitrogen) and quality controlled with the Bioanalyzer 2100 DNA HS assay (Agilent). An equimolar pool was prepared with the 24 libraries and sequenced on a NextSeq 550 (Illumina). 78.9Gb of SE75 reads were produced from two high-output runs. A minimum of 23.97 million reads were obtained for all samples.

The concentration of total RNA extractions was quantified with the Nanodrop One (Thermo Fisher), and RNA integrity was assessed with the Bioanalyzer 2100 RNA Nano assay (Agilent). Libraries for RNA-seq were prepared at the IRB Barcelona Functional Genomics Core Facility. Briefly, mRNA was isolated from 1.5g of total RNA using the kit NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). The isolated mRNA was used to generate dual-indexed cDNA libraries using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (New England Biolabs). Ten cycles of PCR amplification were applied to all libraries.

The final libraries were quantified using the Qubit dsDNA HS assay (Invitrogen) and quality controlled with the Bioanalyzer 2100 DNA HS assay (Agilent). An equimolar pool was prepared with the 12 libraries and submitted for sequencing at the Centre Nacional dAnlisi Genmica (CRG-CNAG). A final quality control by qPCR was performed by the sequencing provider before paired-end 50-nucleotide sequencing on a NovaSeq 6000 S2 (Illumina). Around 77.7Gb of PE50 reads were produced from three NovaSeq 6000 flow cells. A minimum of 55.7 million reads were obtained for all samples (Extended Data Fig. 7).

Total RNA extractions were quantified with a Nanodrop One (Thermo Fisher), and RNA integrity was assessed with the Bioanalyzer 2100 RNA Nano assay (Agilent). Libraries for RNA-seq were prepared at the IRB Barcelona Functional Genomics Core Facility. Briefly, mRNA was isolated from 1.2g of total RNA and used to generate dual-indexed cDNA libraries with the Illumina Stranded mRNA ligation kit (Illumina) and UD Indexes Set A (Illumina). Ten cycles of PCR amplification were applied to all libraries.

Sequencing-ready libraries were quantified using the Qubit dsDNA HS assay (Invitrogen) and quality controlled with the Tapestation HS D5000 assay (Agilent). An equimolar pool was prepared with the 15 libraries for SE75 sequencing on a NextSeq 550 (Illumina). Sequencing output was above 539 million 75-nucleotide single-end reads and a minimum of 28 million reads was obtained for all samples (Extended Data Fig. 7).

All analyses were performed in the R programming language (version 4.0.5)96 unless otherwise stated. Stranded paired-end reads were aligned to the Mus musculus reference genome version mm10 using STAR80 with default parameters. STAR indexes were built using the ENSEMBL annotation version GRC138.97. SAM files were converted to BAM and sorted using sambamba (version 0.6.7)97. Gene counts were obtained with the featureCounts function from the Rsubread package98 with the gtf file corresponding to ENSEMBL version GRC138.97 and parameters set to: isPairedEnd=TRUE and strandSpecific=2. Technical replicates were collapsed by adding the corresponding columns in the count matrix.

We obtained a reprogramming gene signature from published data48 and selected genes with false discovery rate (FDR) lower than 0.05 and fold change between MEF and d3-EFF larger than 2. The reprogramming score was defined as the average of all genes in the signature after scaling the rlog transformed matrix.

Exon counts were generated using the featureCounts function with parameters: isPairedEnd=TRUE, strandSpecific=2, GTF.featureType=exon, GTF.attrType=transcript_id, GTF.attrType.extra=gene_id, allowMultiOverlap=TRUE and useMetaFeatures=FALSE and the same GTF as for gene counts. Technical replicates were collapsed by adding the corresponding counts. For each gene, the longest annotated transcript was selected. Genes with less than four exons of RPKMs lower than exp(2) were discarded from the analysis. Intermediate exons were defined as those from the fourth to the penultimate. A total of 9,365 genes were used to compute the ratio between the intermediate and first exons. Fold changes between untreated and B12-treated samples were computed as the ratio between the exon ratios.

Genes were separated by their expression after transcript length and library size normalization (RPKM). For each sample, we computed the median ratios for genes in each decile.

Data were accessed from GSE131032. Reads were processed and ratios computed as previously described. log2 ratios for all transcripts were summarized through the median by sample. Comparisons between days were performed fitting a linear model to the medians using cage as a covariable. The function glht from the multcomp R package was used to find coefficients and P values.

To select genes most affected by the B12 treatment after reprogramming, we compared ratios between the doxy and MEF conditions and between the doxy and doxy+B12 conditions. Genes that increased the ratios in the first comparison (upper 25th percentile) and decreased the ratio in the second comparison (bottom 25%) were selected for functional enrichment analysis. A hypergeometric test was performed to find significant overlap between the defined gene set and the Biological Processes GO collection99.

Reads were aligned to the mm10 reference genome with bowtie100 version 0.12.9 with parameters --n 2 and --m 1 to keep reads with multiple alignments in one position. SAM files were converted to BAM and sorted using sambamba version 0.6.7.

For each sample, aligned reads were imported into R using the function scanBam from the Rsamtools package101. Whole-genome coverage was computed using the coverage function from the IRanges package102 and binned into 50-bp windows. Gene annotations were imported from Ensembl version GRCm38. The average coverage over gene bodies was computed using the normalizeToMatrix function from the EnrichedHeatmap package103 with parameters extend=1,000, mean_mode=w0 and w=50. Genes were filtered to coincide with those used in the exon ratio calculation from the RNA-seq data. Rows in the heat map were split by the average RNA-seq RPKM values in all samples.

BAM files were transformed to TDF files using the count function from IGVtools (version 2.12.2)104 with parameters --z 7, --w 25 and --e 250. Visualization of TDF files was generated using IGV (version 2.9.4)105.

Data were accessed from GSE109142. Reads were processed and ratios computed as previously described except using the ENSEMBL GRCm38.101 human gene annotation and the hg38 genome assembly version. The log2 ratios for all transcripts were summarized through the median by sample. Comparison between diagnosis status was performed fitting a linear model to the medians with sex and the expression quantiles as covariables. The model was fitted using the lm R function and coefficients and P values with the coeff function.

Unless otherwise specified, data are presented as the means.d. Statistical analysis was performed by Students t-test or one-way analysis of variance (ANOVA) as indicated, using GraphPad Prism v9.0.0, and specific statistical tests as indicated for each experiment for bioinformatic analyses. P values of less than 0.05 were considered as statistically significant. No statistical methods were used to predetermine sample size in the mouse studies, but our sample sizes are similar to those reported in previous publications3,9,16,17,19. Animals and data points were not excluded from analysis with the exception of the MEFs that failed to reprogram in the ChIP experiment, which is clearly detailed in the text. Mice were allocated at random to treatment groups, with attempts to balance initial body weight and sex as possible. The investigators were blinded during histological assessment of the mice; other data collection and analysis was not performed blind to the conditions of the experiments. Data distribution was assumed to be normal, but this was not formally tested. Figures were prepared using Illustrator CC 2019 (Adobe).

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

See the article here:
Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com

Using patients’ own cells, researchers examine connection between … – ND Newswire

Although considered a rare disorder, fragile X syndrome is the most common genetic cause of intellectual disability in the world. Fragile X patients can have a range of mild to severe intellectual disability with the potential for other conditions such as autism, delayed motor development, hyperactivity, behavioral problems and seizures.

Although its well-known that fragile X is caused by the FMR1 gene, its less understood how the disorder physically affects brain development and function.

Christopher Patzke, the John M. and Mary Jo Boler Assistant Professor of Biological Sciences at the University of Notre Dame, is collaborating with fragile X patients and families to study the disorder.

My lab is hoping to find an explanation of the disease symptoms in humans, looking at the disorder at the cellular and molecular level, Patzke said.

By partnering with fragile X expert Dr. Elizabeth M. Berry-Kravis, professor of pediatrics at Rush University and a 1979 graduate of Notre Dame, the Patzke Lab has been able to collect patient tissue samples to create induced pluripotent stem cells. Because these stem cells mimic embryonic stem cells, the lab can then transform those cells into virtually any human cell the researchers want to study.

For this research, Patzke and his team are transforming pluripotent stem cells into brain cells that mimic neurons of someone with fragile X syndrome, creating a human model to study the genetic mutations effect on the brain.

Most of the genes associated with intellectual disability encode for proteins that do something with synapses, Patzke said. So making a cell culture of these fragile X neurons allows us, in a way, to zoom in to single cells and synapses, or the connections between neurons, and learn how these neurons communicate with one another.

The researchers then compare a patients cell culture sample to a corrected-cell culture sample, made via gene editing, to analyze the differences between how the synapses function with and without the FMR1 gene mutation.

Although research into fragile X syndrome is not uncommon, many researchers use animal models to study the FMR1 gene. While some of the research has led to clinical trials, those results have yet to translate into effective benefits for humans. By using tissue from fragile X patients, the goal is to overcome this gap in discovery.

In addition to fragile X syndrome, the Patzke Lab is also studying other disorders that cause intellectual disability including Down syndrome and Kabuki syndrome, another rare disorder.

Patzke is affiliated with Notre Dames Boler-Parseghian Center for Rare and Neglected Diseases, the first basic science rare disease research center in the nation. Focused on both basic and translational research, the center works with families affected by rare diseases to combine studies of patient data and tissue with fundamental biological research in order to better understand disease, identify molecular targets and develop new diagnostics and treatments.

Contact: Brandi Wampler, associate director of media relations, 574-631-2632, brandiwampler@nd.edu

Link:
Using patients' own cells, researchers examine connection between ... - ND Newswire

Seven Salk scientists named among best and most highly cited … – Salk Institute

November 15, 2023 November 15, 2023

LA JOLLASalk Professors Joseph Ecker, Ronald Evans, Satchidananda Panda, Rusty Gage, and Kay Tye, as well as Assistant Professor Jesse Dixon, have been named to the Highly Cited Researchers list by Clarivate. The 2023 list includes 6,849 researchers from 67 countries, all of whom demonstrate significant and broad influence reflected in their publication of multiple highly cited papers over the last decade. This is the ninth consecutive year that Ecker and Gage have made the list. Joseph Nery, a research assistant II in the Ecker lab, was also included on the list.

The Highly Cited Researchers list identifies and celebrates exceptional individual researchers at Salk, whose significant and broad influence in their fields translates to impact in their research community and innovations that make the world healthier, more sustainable, and more secure, says David Pendlebury, Head of Research Analysis at the Institute for Scientific Information at Clarivate. Their contributions resonate far beyond their individual achievements, strengthening the foundation of excellence and innovation in research.

Joseph Ecker Ecker is a professor in the Plant Molecular and Cellular Biology Laboratory, the director of the Genomic Analysis Laboratory, the Salk International Council Chair in Genetics, and a Howard Hughes Medical Institute investigator. His current research focuses on genomic and epigenomic regulation in plants and mammals and the application of DNA sequencing technologies for genome-wide analysis of DNA methylation, chromatin conformation, transcription, and gene function in single cells.

Ronald Evans Evans is a professor, the director of the Gene Expression Laboratory, and the March of Dimes Chair in Molecular and Developmental Biology. An expert in the essential roles of hormone receptors in reproduction, growth, and metabolism, Evans has identified novel pathways involved in cancer and metabolic diseases that are targetable by drugs that activate these receptors. More than a dozen approved drugs have been developed with Evans' technology for the treatment of leukemia, prostate cancer, breast cancer, liver disease, diabetes, and hypertension.

Satchidananda Panda Panda is a professor in the Regulatory Biology Laboratory and the director of the Wu Tsai Human Performance Alliance at Salk. He aims to understand how diet, exercise, and sleep affect cells and molecules in our body and to leverage this knowledge to elevate performance and reduce chronic diseases.

Rusty Gage Gage is a professor in the Laboratory of Genetics, the Vi and John Adler Chair for Research on Age-Related Neurodegenerative Disease, and the former president of the Salk Institute. He is a neuroscientist who studies the plasticity, adaptability, and diversity of the brain. By reprogramming human skin cells and other cells from patients with neurologic and psychiatric diseases into induced pluripotent stem cells, induced neurons, and organoids, his work is deciphering the progression and mechanisms that lead to disorders such as Alzheimer's disease, Parkinsons disease, bipolar disease, depression, and autism spectrum disorder.

Kay Tye Tye is a professor in the Systems Neurobiology Laboratory and the Wylie Vale Chair. She seeks to understand the neural-circuit basis of emotion that leads to motivated behaviors such as social interaction, reward-seeking, and avoidance. Her findings may help to inform treatments for a multitude of neuropsychiatric conditions such as anxiety, depression, addiction, and impairments in social behavior.

Jesse Dixon Dixon, a physician-scientist, is an assistant professor in the Gene Expression Laboratory and a member of the Salk Cancer Center faculty. He is a molecular biologist who uses molecular and computational approaches to explore how our genomes are organized in cells and how abnormal genome folding leads to human diseases such as cancer. His team is also developing new methods to study gene organization and gene function in single cells.

Joseph Nery Nery is a research assistant in the Ecker lab. He has been at the Salk Institute since 2006, where he specializes in epigenetics and runs computational analyses for the lab.

Here is the original post:
Seven Salk scientists named among best and most highly cited ... - Salk Institute

Perspectives of current understanding and therapeutics of Diamond … – Nature.com

Bartels M, Bierings M. How I manage children with Diamond-Blackfan anaemia. Br J Haematol. 2019;184:12333.

Article PubMed Google Scholar

Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021;6:323.

Article CAS PubMed PubMed Central Google Scholar

Dianzani I, Loreni F. Diamond-Blackfan anemia: a ribosomal puzzle. Haematologica. 2008 ;93:16014.

Article CAS PubMed Google Scholar

Ulirsch JC, Verboon JM, Kazerounian S, Guo MH, Yuan D, Ludwig LS, et al. The genetic landscape of Diamond-Blackfan anemia. Am J Hum Genet. 2018;103:93047.

Article CAS PubMed PubMed Central Google Scholar

Liu Y, Dahl M, Debnath S, Rothe M, Smith EM, Grahn THM, et al. Successful gene therapy of Diamond-Blackfan anemia in a mouse model and human CD34(+) cord blood hematopoietic stem cells using a clinically applicable lentiviral vector. Haematologica. 2022;107:44656.

Article CAS PubMed Google Scholar

Josephs HW. Anaemia of infancy and early childhood. Medicine. 1936;15:307451.

Article Google Scholar

Louis K, Diamond KB. Hypoplastic anemia. Am J Dis Child. 1938;56:4647.

Google Scholar

Gasser C. [Aplastic anemia (chronic erythroblastophthisis) and cortisone]. Schweiz Med Wochenschr. 1951;81:12412.

CAS PubMed Google Scholar

Allen DM, Diamond LK. Congenital (erythroid) hypoplastic anemia: cortisone treated. Am J Dis Child. 1961;102:41623.

Article CAS PubMed Google Scholar

August CS, King E, Githens JH, McIntosh K, Humbert JR, Greensheer A, et al. Establishment of erythropoiesis following bone marrow transplantation in a patient with congenital hypoplastic anemia (Diamond-Blackfan syndrome). Blood. 1976;48:4918.

Article CAS PubMed Google Scholar

Glader BE, Backer K, Diamond LK. Elevated erythrocyte adenosine deaminase activity in congenital hypoplastic anemia. N Engl J Med. 1983;309:148690.

Article CAS PubMed Google Scholar

Gustavsson P, Willing TN, van Haeringen A, Tchernia G, Dianzani I, Donner M, et al. Diamond-Blackfan anaemia: genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb. Nat Genet. 1997;16:36871.

Article CAS PubMed Google Scholar

Gustavsson P, Skeppner G, Johansson B, Berg T, Gordon L, Kreuger A, et al. Diamond-Blackfan anaemia in a girl with a de novo balanced reciprocal X;19 translocation. J Med Genet. 1997;34:77982.

Article CAS PubMed PubMed Central Google Scholar

Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, et al. The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet. 1999;21:16975.

Article CAS PubMed Google Scholar

Gazda H, Lipton JM, Willig TN, Ball S, Niemeyer CM, Tchernia G, et al. Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease. Blood. 2001;97:214550.

Article CAS PubMed Google Scholar

Klar J, Khalfallah A, Arzoo PS, Gazda HT, Dahl N. Recurrent GATA1 mutations in Diamond-Blackfan anaemia. Br J Haematol. 2014;166:94951.

Article CAS PubMed Google Scholar

Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012;122:243943.

Article CAS PubMed PubMed Central Google Scholar

Jaako P, Flygare J, Olsson K, Quere R, Ehinger M, Henson A, et al. Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood. 2011;118:608796.

Article CAS PubMed Google Scholar

Liu Y, Schmiderer L, Hjort M, Lang S, Bremborg T, Rydstrom A, et al. Engineered human Diamond-Blackfan anemia disease model confirms therapeutic effects of clinically applicable lentiviral vector at single-cell resolution. Haematologica. 2023;108:3095109.

Voit RA, Corey SJ. Gene therapy for congenital marrow failure syndromes - no longer grasping at straws? Haematologica. 2023;108:28802882.

Vlachos A, Muir E. How I treat Diamond-Blackfan anemia. Blood. 2010;116:371523.

Article CAS PubMed PubMed Central Google Scholar

Da Costa L, Leblanc T, Mohandas N. Diamond-Blackfan anemia. Blood. 2020;136:126273.

Article PubMed PubMed Central Google Scholar

Vlachos A, Ball S, Dahl N, Alter BP, Sheth S, Ramenghi U, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol. 2008;142:85976.

Article CAS PubMed PubMed Central Google Scholar

Faivre L, Meerpohl J, Da Costa L, Marie I, Nouvel C, Gnekow A, et al. High-risk pregnancies in Diamond-Blackfan anemia: a survey of 64 pregnancies from the French and German registries. Haematologica. 2006;91:5303.

PubMed Google Scholar

Flores Ballester E, Gil-Fernandez JJ, Vazquez Blanco M, Mesa JM, de Dios Garcia J, Tamayo AT, et al. Adult-onset Diamond-Blackfan anemia with a novel mutation in the exon 5 of RPL11: too late and too rare. Clin Case Rep. 2015;3:3925.

Article PubMed PubMed Central Google Scholar

Fargo JH, Kratz CP, Giri N, Savage SA, Wong C, Backer K, et al. Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia. Br J Haematol. 2013;160:54754.

Article CAS PubMed Google Scholar

Glader BE, Backer K. Elevated red cell adenosine deaminase activity: a marker of disordered erythropoiesis in Diamond-Blackfan anaemia and other haematologic diseases. Br J Haematol. 1988;68:1658.

Article CAS PubMed Google Scholar

Matsson H, Davey EJ, Draptchinskaia N, Hamaguchi I, Ooka A, Leveen P, et al. Targeted disruption of the ribosomal protein S19 gene is lethal prior to implantation. Mol Cell Biol. 2004;24:40327.

Article CAS PubMed PubMed Central Google Scholar

Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA, et al. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol. 2004;2:E139.

Article PubMed PubMed Central Google Scholar

Gianferante MD, Wlodarski MW, Atsidaftos E, Da Costa L, Delaporta P, Farrar JE, et al. Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in RPL35A. Haematologica. 2021;106:130310.

Article PubMed Google Scholar

Noel CB. Diamond-Blackfan anemia RPL35A: a case report. J Med Case Rep. 2019;13:185.

Article PubMed PubMed Central Google Scholar

Tamefusa K, Muraoka M, Washio K, Wakamatsu M, Shimada A. Late-onset familial Diamond-Blackfan anemia with neutropenia caused by RPL35A variant. Pediatr Int. 2022;64:e15275.

Article PubMed Google Scholar

Gazda HT, Sheen MR, Vlachos A, Choesmel V, ODonohue MF, Schneider H, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am J Hum Genet. 2008;83:76980.

Article CAS PubMed PubMed Central Google Scholar

Quarello P, Garelli E, Carando A, Cillario R, Brusco A, Giorgio E, et al. A 20-year long term experience of the Italian Diamond-Blackfan Anaemia Registry: RPS and RPL genes, different faces of the same disease? Br J Haematol. 2020;190:93104.

Article CAS PubMed Google Scholar

Ferreira R, Ohneda K, Yamamoto M, Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol. 2005;25:121527.

Article CAS PubMed PubMed Central Google Scholar

Ludwig LS, Gazda HT, Eng JC, Eichhorn SW, Thiru P, Ghazvinian R, et al. Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med. 2014;20:74853.

Article CAS PubMed PubMed Central Google Scholar

Gripp KW, Curry C, Olney AH, Sandoval C, Fisher J, Chong JX, et al. Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28. Am J Med Genet A. 2014;164A:22409.

Article PubMed Google Scholar

ODonohue MF, Da Costa L, Lezzerini M, Unal S, Joret C, Bartels M, et al. HEATR3 variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia. Blood. 2022;139:311126.

Article PubMed PubMed Central Google Scholar

Yang YM, Karbstein K. The chaperone Tsr2 regulates Rps26 release and reincorporation from mature ribosomes to enable a reversible, ribosome-mediated response to stress. Sci Adv. 2022;8:eabl4386.

Article CAS PubMed PubMed Central Google Scholar

Kim AR, Ulirsch JC, Wilmes S, Unal E, Moraga I, Karakukcu M, et al. Functional selectivity in cytokine signaling revealed through a pathogenic EPO mutation. Cell. 2017;168:105364.e1015.

Article CAS PubMed PubMed Central Google Scholar

Szvetnik EA, Klemann C, Hainmann I, O Donohue M-F, Farkas T, Niewisch M, et al. Diamond-Blackfan anemia phenotype caused by deficiency of adenosine deaminase 2. Blood. 2017;130:874.

Mills EW, Green R. Ribosomopathies: theres strength in numbers. Science. 2017;358:eaan2755.

Liu Y, Deisenroth C, Zhang Y. RP-MDM2-p53 pathway: linking ribosomal biogenesis and tumor surveillance. Trends Cancer. 2016;2:191204.

Article PubMed PubMed Central Google Scholar

Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20:199210.

Article CAS PubMed Google Scholar

Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16:36977.

Article CAS PubMed PubMed Central Google Scholar

Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood. 2008;112:522837.

Article CAS PubMed Google Scholar

Moniz H, Gastou M, Leblanc T, Hurtaud C, Cretien A, Lecluse Y, et al. Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro. Cell Death Dis. 2012;3:e356.

Article CAS PubMed PubMed Central Google Scholar

Chakraborty A, Uechi T, Higa S, Torihara H, Kenmochi N. Loss of ribosomal protein L11 affects zebrafish embryonic development through a p53-dependent apoptotic response. PLoS One. 2009;4:e4152.

Article PubMed PubMed Central Google Scholar

Torihara H, Uechi T, Chakraborty A, Shinya M, Sakai N, Kenmochi N. Erythropoiesis failure due to RPS19 deficiency is independent of an activated Tp53 response in a zebrafish model of Diamond-Blackfan anaemia. Br J Haematol. 2011;152:64854.

Article CAS PubMed Google Scholar

Devlin EE, Dacosta L, Mohandas N, Elliott G, Bodine DM. A transgenic mouse model demonstrates a dominant negative effect of a point mutation in the RPS19 gene associated with Diamond-Blackfan anemia. Blood. 2010;116:282635.

Article CAS PubMed PubMed Central Google Scholar

McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008;40:96370.

Article CAS PubMed PubMed Central Google Scholar

Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood. 2011;117:256776.

Article CAS PubMed PubMed Central Google Scholar

Here is the original post:
Perspectives of current understanding and therapeutics of Diamond ... - Nature.com